Ronald Peck - Feb 23, 2024 Form 4 Insider Report for ARVINAS, INC. (ARVN)

Role
Chief Medical Officer
Signature
/s/ Jared Freedberg, as attorney-in-fact for Ronald Peck
Stock symbol
ARVN
Transactions as of
Feb 23, 2024
Transactions value $
-$79,938
Form type
4
Date filed
2/27/2024, 06:34 PM
Previous filing
Aug 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARVN Common Stock Award $0 +39.3K +130.99% $0.00 69.2K Feb 23, 2024 Direct F1
transaction ARVN Common Stock Sale -$79.9K -1.7K -2.45% $47.05 67.5K Feb 23, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARVN Stock Option (right to buy) Award $0 +58.1K $0.00 58.1K Feb 23, 2024 Common Stock 58.1K $47.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units (each, an "RSU") were granted by the Issuer on February 23, 2024, pursuant to its 2018 Stock Incentive Plan (the "Plan") and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over two years: 1/2 of the shares underlying the award shall vest on February 23, 2025, with the remainder of the shares vesting on February 23, 2026.
F2 This sale was made to cover withholding taxes following the vesting of previously granted Restricted Stock Units.
F3 The option was granted by the Issuer on February 23, 2024, pursuant to the Plan. The shares underlying the option will vest over two years: 1/2 of the shares underlying the award shall vest on February 23, 2025, with the remainder of the shares vesting on February 23, 2026.